Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder

American Journal of Transplantation

Volumn 12, Issue 5, 2012, Pages 1268-1274

  Engels, E A ^a   Preiksaitis, J ^b   Zingone, A ^a   Landgren, O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Epstein Barr virus; immunology; lymphocyte activation; monoclonal gammopathy of undertermined significance; posttransplant lymphoproliferative disorder; tumor markers

Indexed keywords

POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; KAPPA STATISTICS; LIGHT CHAIN; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 84860428114     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03954.x     Document Type: Article

References (33)

1. Vajdic CM, van Leeuwen MT,. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754.
2. Harris NL, Swerdlow SH, Frizzera G, Knowles DM,. Post-transplant lymphoproliferative disorders. In:, Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001: 264-269.
3. Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cursaro C, Pileri S, et al,. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163: 1997-2004.
4. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA,. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206-209.
5. Ghobrial IM, Habermann TM, Macon WR, et al,. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases Transplantation 2005; 79: 244-247.
6. Opelz G, Daniel V, Naujokat C, Dohler B,. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
7. Allen U, Preiksaitis J,. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S87-S96.
8. Mawhorter S, Yamani MH,. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13: 581-585.
9. Claas FH,. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 2010; 15: 462-466.
10. Tsai DE, Aqui NA, Tomaszewski JE, et al,. Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant 2005; 19: 644-652.
11. Peest D, Schaper B, Nashan B, et al,. High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. Transplantation 1988; 46: 389-393.
12. Rosselet A, Vu DH, Meylan P, et al,. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. Clin Transplant 2009; 23: 74-82.
13. Badley AD, Portela DF, Patel R, et al,. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375-382.
14. Landgren O, Goedert JJ, Rabkin CS, et al,. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28: 773-779.
15. Bradwell AR, Carr-Smith HD, Mead GP, et al,. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
16. Rajkumar SV, Kyle RA, Buadi FK,. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85: 945-948.
17. Maurer MJ, Cerhan JR, Katzmann JA, et al,. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011; 118: 2821-2826.
18. Hutchison CA, Landgren O,. Polyclonal immunoglobulin free light chains as a potential marker of immune stimulation and inflammation. Clin Chem 2011; 57: 1387-1389.
19. Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR,. Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 2002; 264: 19-28.
20. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR,. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
21. Rowe DT, Qu L, Reyes J, et al,. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612-1615.
22. Trotta MP, Lorenzini P, Bibas M, et al,. Relative prognostic value of serum-free light chains and effective HAART in predicting HIV-associated lymphoma and mortality (abstract). In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston.
23. Vendrame E, Martinez-Maza O,. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: Insights on the etiology of lymphoma. J Proteome Res 2011; 10: 113-119.
24. Gottenberg JE, Aucouturier F, Goetz J, et al,. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 23-27.
25. Terrier B, Sene D, Saadoun D, et al,. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009; 68: 89-93.
26. Solling K, Solling J, Romer FK,. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 1981; 209: 473-477.
27. Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR,. Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 2002; 264: 19-28.
28. Babel N, Schwarzmann F, Pruss A, Volk HD, Reinke P,. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc 2004; 36: 2679-2682.
29. Hutchison CA, Harding S, Hewins P, et al,. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690.
30. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59-67.
31. de Milito A,. B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2004; 2: 11-21.
32. Haque T, Chaggar T, Schafers J, Atkinson C, McAulay KA, Crawford DH,. Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011; 83: 311-316.
33. Barton M, Wasfy S, Hebert D, et al,. Exploring beyond viral load testing for EBV lymphoproliferation: Role of serum IL-6 and IgE assays as adjunctive tests. Pediatr Transplant 2010; 14: 852-858.